Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

NRX.V Relative to the S&P 500

Seasonal Chart Analysis

Analysis of the NurExone Biologic Inc. (TSXV:NRX.V) seasonal charts above shows that a Buy Date of November 1 and a Sell Date of January 31 has resulted in a geometric average return of 6.49% above the benchmark rate of the S&P 500 Total Return Index over the past 12 years. This seasonal timeframe has shown positive results compared to the benchmark in 8 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 12 years by an average of 4.61% per year.

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

To download NRX.V seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: NRX.V